Our mission is to ensure the generation of accurate and precise findings.
Please enter subscribe form shortcode
Please enter instagram feed shortcode
Our carefully curated network is rooted in stringent quality standards. Through a rigorous selection and auditing process, we ensure our manufacturing partners meet the highest industry standards, delivering excellence across every stage of production.
From in-process inspections to final product testing, we uphold strict quality protocols to guarantee consistency and safety.
Our partner facilities feature cutting-edge technologies like lyophilization and aseptic filling, supporting precision and reliability in every batch.
We assess our CMOs' capabilities to ensure they can meet current and future production demands. Our criteria include financial stability and strategic geographic locations for seamless delivery worldwide.
Their robust infrastructure enables us to produce complex formulations with precision, ensuring that every product meets the highest standards of quality and efficacy.
Finoso Pharma’s product selection process is designed to maximize market impact, leveraging our R&D strengths and strategic insights.
We prioritize products with high market demand, extensive geographic reach, and a clear competitive advantage.
With a focus on early post-patent-expiry launches, we ensure strategic entry into competitive markets.
Our team brings extensive experience in developing both simple and complex injectables, aligning each product with rigorous regulatory standards.
We select products that align closely with our partners' objectives, providing solutions that meet their strategic and operational goals.
Our approach balances development and market expansion costs, ensuring multi-market filings and robust portfolio management.
Priyaranjan Pattanaik holds Bachelor and Master Degree in Pharmaceutical Technology from Biju Patnaik University, Bhubaneswar.
He has over 12 years of experience in formulation research. Prior to his stint with Finoso Pharma, he worked with R&D centres of Indian leading pharma companies like Micro labs, Medreich, Indoco Remedies, Hetero Labs and Optimus Pharma. He has varied experience that encompasses activities from formulation development to product approvals for the US, Canada, Europe and other regulated markets along with other emerging markets. He managed product development programs from initiation, development strategy, risk assessment analysis, infringement analysis and regulatory filings of generic products.
This will close in 0 seconds
Sanjay holds a Bachelor’s Degree in Chemistry from Mumbai University, Maharashtra, India and Master’sDegree in Analytical Chemistry from Mumbai University, Maharashtra, India. He has over 16 years of experience in Analytical Research and Development of APIs and various finished dosage forms. Prior to his stint at Finoso Pharma, he worked with companies like CIPLA, Dr. Reddy’s Laboratoriesand Aizant.
He has extensive knowledge and experience in Method Development, Method Validations, Method Transfers, Laboratory Management (LIMS, CFR Part 11 Compliance), Stability Studies, and Packaging Material Testing. He is an expert in handling wide range of analytical instruments including HPLC, UPLC, TGA, DSC, AAS, GC with TCD and ECD, Laser Diffraction Particle Size Analyzers, pXRD, UV, FTIR etc. He has vast experience in end to end delivery of various NDA, ANDA & NCE-1 projects.
He has developed and validated analytical methods for Assay, Related Substances, and Dissolutions etc. for various types of dosage forms like tablets, pellets, injectable, inhalers, gels, suspensions, syrups, capsules, ointments and creams. He has adequate exposure in handling regulatory questions on analytical methods from USFDA, UK MHRA, Health Canada and other leading agencies.
This will close in 0 seconds
Director (Board Member of Finoso Management) - Finoso Pharma & Chief Technical Officer - Vivimed Labs
Dillip obtained his Master’s in Pharmaceutical & Pharmaceutical Technology from LM college of Pharmacy, Ahmedabad, Gujarat India. He has about 15 plus years of work experience in Research & Development, Business Development and Manufacturing Plant operations.
He worked in the Innovation &Generic Pharmaceutical industry for over 15 years, handling product and process development activities. During this time, he was responsible for developing several solid and liquid dosage form products and got several ANDAs approved by the US FDA, MHRA, Health Canada, TGA etc. After leading formulation Development teams in companies like ZydusCadila, Mylan Laboratories Ranbaxy Research Laboratory, India & Dr.Reddy’s Laboratories he moved to Aizant for setting up In house products portfolio. Under his visionary leadership Aizant filed & got approval for multiple complex generic and NCE-1 products.After his successful stint at Aizant, he took the responsibility asPresident R&D and Operations at Optimus pharma where he played important role in reforming the business model, under his visionary and vibrant leadership Optimus pharma observed the peaks of growth. Optimus was amongst few first Indian companies to launch & get approval for anti-corona Favipiravir Tablets.
He has rich experience that encompasses activities from formulation development to product approvals for the US, Europe and other regulated markets. He managed entire product development program from molecule selection, development strategy, risk assessment analysis, infringement analysis and regulatory filings of generic products. He has several patents, at various stages, to his credit. He was exposed to generic product development from Para I to Para IV filings and he has substantial experience in filing NDAs as well.
Dillip has hands on experience in developing formulations of Antidepressant, Anti-allergic, Antiviral, Anti-diabetic and Cardiovascular drugs. His research projects included development of Para IV / modified release / sustained release generic formulations based on matrix / palletization / osmotic delivery technologies for oral solid dosage forms. He has several publications and research papers to his credit.
He joined Finoso Pharma in Aug 2020 and has been running the company successfully ever since as its Director& CTO.
This will close in 0 seconds
This will close in 0 seconds
This will close in 0 seconds
This will close in 0 seconds
This will close in 0 seconds
This will close in 0 seconds